So what are the drugs coming through the pipeline
When a patient shares a story of devastating injury, the last thing I Statement on Lilly's announcement of "impurity" in compounded tirz+B12 Mar 12, 2026 Statement on Lilly's announcement of "impurity" in compounded tirz+B12 Scott Brunner, CAE March 12, 2026 12:30PM EDST Lillys announcement today that it has observed impurities in How FDA inaction on peptides empowers the gray market Mar 5, 2026 How FDA inaction on peptides empowers the gray market HHS Secretary Robert F
GLP-1 receptor agonists were designed with these challenges in mind, which is why currently approved medications rely on injectable or highly specialized oral delivery systems
Protein-rich diets are known to support muscle protein synthesis, particularly during calorie deficits induced by GLP-1 medications (Longland et al., 2016)
Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine
What we like about a two product, targeted approach is that it attempts to address both directions of the GLP-1 pathway: Direct activation of L cells and receptor signalling Indirect support through the gut microbiome and metabolic environment That means we are not just telling the body to release more GLP-1, but also creating the conditions for GLP-1 to be more effective and longer lasting